Answers are grounded in this paper and cite their sources.
Innovative tools enhance product characterization and quality control in RNA therapeutics, indicating improved manufacturability and regulatory trust.
“As RNA therapeutics continue their journey from niche technologies to mainstream medicines ... it has become a strategic enabler of innovation, manufacturability and regulatory confidence.
No takes yet. Share an insight, caveat, or question.
Jeske Smink (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: